Login to Your Account



EFFICACY AND SAFETY AREN'T THE PROBLEM

An alarming rate of cancer clinical trials ending early

By Brian Orelli
Contributing Writer

Monday, February 3, 2014

Last week, Cambridge, Mass.-based Aveo Oncology and Astellas Pharma Inc., of Tokyo, announced that they were discontinuing a Phase II trial testing tivozanib in patients with locally recurrent or metastatic triple negative breast cancer due to insufficient enrollment.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription